Revenio Group (REG1V) Q4 2025 earnings summary

Executive summary

• Net sales for 2025 increased by 6.0% year-over-year to EUR 109.7 million, with currency-adjusted growth at 9.1%.

• Strong sales growth in the US (all-time record in December) and EMEA; APAC improved over Q3 but was down year-over-year.

• Cash flow from operations reached a record EUR 30.2 million, with Q4 at EUR 15.9 million.

• All product categories grew in 2025, with notable expansion in hardware, screening solutions, and software contracts.

• Strategic focus included product innovation, solution launches, sales and marketing investments, and leadership development.

Financial highlights

• Q4 EBIT was EUR 6.7 million, down 26.9% year-over-year; full-year EBIT was EUR 25.4 million, up 1.4%.

• Q4 EPS was EUR 0.208; full-year EPS was EUR 0.655.

• Gross margin for 2025 was 70.9%, up 0.7 percentage points; Q4 gross margin was 67.6%, down 4.8 percentage points.

• Net gearing improved to -13.3%, reflecting a strong balance sheet.

• Cash flow in Q4 was strong, with no significant exceptional items aside from a minor tax return.

Outlook and guidance

• 2026 guidance: exchange rate-adjusted net sales expected to grow 8–15% year-over-year; profitability (excluding non-recurring items) to remain at a good level.

• Price increases in the US are being implemented to offset tariffs, with gross margin expected to move closer to 70% as these take effect.

• Clinical trial costs for FDA approval of DRSplus expected to be EUR 1–1.5 million in 2026, with approval targeted by end of H1 2027.

• Strategic focus for 2026 includes intensified sales and marketing, continued R&D investment, and M&A opportunities.